Bone-Modifying Agents in Early Breast Cancer: Making Sense of Conflicting Data.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319831.
- Also identified by DOI 10.1056/EVIDe2200259.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The use of adjuvant bone-modifying agents to reduce risk of recurrence in patients with early-stage breast cancer has not been widely embraced because of conflicting data and small absolute benefits. The clinical practice guideline produced jointly by the American Society of Clinical Oncology and Cancer Care Ontario recommends discussion of risks/benefits with postmenopausal patients with early-stage breast cancer about adjuvant bisphosphonates and does not recommend use of adjuvant denosumab to prevent breast cancer recurrence.<sup>1</sup>.
Medical subject headings
- Breast Neoplasms